Aclaris Therapeutics, Inc. (ACRS) News
Filter ACRS News Items
ACRS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ACRS News Highlights
- ACRS's 30 day story count now stands at 2.
- Over the past 14 days, the trend for ACRS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- SUN, ATI and DEC are the most mentioned tickers in articles about ACRS.
Latest ACRS News From Around the Web
Below are the latest news stories about ACLARIS THERAPEUTICS INC that investors may wish to consider to help them evaluate ACRS as an investment opportunity.
Aclaris Therapeutics Provides Corporate Update- ATI-1777 Phase 2a Trial Results Published in JID Innovations -- ATI-1777 Phase 2b Trial Topline Data Anticipated in January 2024 -- Aclaris Announces Reduction in Workforce - WAYNE, Pa., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced several corporate updates. First, Aclaris announced the publication of the Phase 2a trial results of ATI-17 |
Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for AlopeciaWAYNE, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced an exclusive patent license agreement with Sun Pharmaceutical Industries, Inc. (Sun Pharma). Under the license agreement, Aclaris granted Sun Pharma exclusive rights under certain patents for the use of deuruxolitinib, Sun Pharma’s JAK inhibitor, or other isotopic forms of ruxolitini |
Aclaris (ACRS) Loses -83.17% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerAclaris (ACRS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
Down -84.82% in 4 Weeks, Here's Why You Should You Buy the Dip in Aclaris (ACRS)Aclaris (ACRS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
Aclaris (ACRS) Lead Drug Fails Rheumatoid Arthritis StudyAclaris (ACRS) decides to stop the development of its lead drug after top-line data from a mid-stage study did not achieve any study goals. Shares plunge 86% following the news. |
Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update— Study Did Not Meet Primary or Secondary Efficacy Endpoints in Rheumatoid Arthritis — — Efficacy Results Do Not Support Further Development of Zunsemetinib — — Company to Host Conference Call and Webcast Today at 8:00 AM ET — WAYNE, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced top-line results from a Phase 2b study of zunsemetinib (A |
Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This WeekCelebrations may be in order for Aclaris Therapeutics, Inc. ( NASDAQ:ACRS ) shareholders, with the analysts delivering... |
Aclaris Therapeutics Inc (ACRS) Reports Q3 2023 Financial ResultsCompany's cash, cash equivalents and marketable securities stand at $187.0 million as of Q3 2023 |
Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update- Topline Data from Zunsemetinib Phase 2b Trial in Rheumatoid Arthritis Expected this Month – - Completion of Enrollment in ATI-1777 Phase 2b Trial in Atopic Dermatitis As Previously Announced; Topline Data Anticipated Around Year-End 2023 - WAYNE, Pa., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the th |
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)- Top-line Data Anticipated Around Year End WAYNE, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the completion of enrollment into ATI-1777-AD-202, its Phase 2b trial of its investigational topical “soft” Janus kinase (JAK) 1/3 inhibitor, ATI-1777, in patients with mild to severe atopic dermatitis. Aclaris anticipates releasi |